nach oben

Journal of Gambling Studies

Erschienen in:

01.09.2015 | Original Paper

Dopaminergic Medication in Parkinson’s Disease and Problem Gambling

verfasst von: Jacqueline Olley, Alex Blaszczynski, Simon Lewis

Erschienen in: Journal of Gambling Studies | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Studies on Parkinson’s disease patients on dopaminergic medication report elevated rates of problem gambling. Results suggest changes in gambling behaviour are associated with the commencement and termination of dopaminergic medication implying a direct causal relationship. However, previous reports have not controlled for possible factors independent of dopamine medication contributing to the onset of problem gambling. This study aimed to explore the temporal relationships between problem gambling and dopamine medication taking into account premorbid gambling risk factors in a sample of Parkinson’s disease patients. Twenty patients with Parkinson’s disease meeting criteria for moderate risk or problem gambling were compared to twenty patients with Parkinson’s disease who did not meet such criteria. The cross-sectional research design compared between group qualitative and quantitative differences. Participants completed an in-depth interview and timeline follow back, and battery of psychometric measures assessing impulsivity, gambling status, affective states, and obsessionality. Results revealed a complex and varied temporal relationship between dopaminergic medication onset and gambling. A small number of participants manifested excessive gambling following dopaminergic medication, with some ceasing on reduction in dosage or change in agonist class. Many demonstrated a range of individual and situational characteristic similar to problem gamblers in the general population, and in older adults with gambling problems. The obtained results provide a better understanding of the role of dopaminergic medication in problem gambling. Such findings have theoretical relevance to the reward deficiency model of gambling and have implications for the treatment of pathological gambling in PD and the general community.

Albrecht, U., Kirschner, N., & Grusser, S. (2007). Diagnostic instruments for behavioural addiction: An overview. GMS Psych-Social-Medicine, 4, 1–11.

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.

Avanzi, M., Baratti, M., Cabrini, S., Uber, E., Brighetti, G., & Bonfa, F. (2005). Prevalence of pathological gambling in patients with Parkinson’s disease. Movement Disorder, 21, 2068–2072.CrossRef

Blaszczynski, A., & Nower, L. (2002). A pathways model of problem and pathological gambling. Addiction, 97(5), 487–499.CrossRefPubMed

Blum, K., Braverman, E., Holder, J., Lubar, J., Monastra, V., Miller, D., et al. (2000). Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive and compulsive behaviours. Journal of Psychoactive Drugs, 3, 100–112.

Blum, K., Sheridan, P., Wood, R., Braverman, E., & Comings, D. (1996). The reward deficiency syndrome. American Scientist, 84, 132–145.

Bodi, N., Keri, S., Nagy, H., Moustafa, A., Myers, C., Daw, N., et al. (2009). Reward-learning and the novelty-seeking personality: A between- and within-subjects study of the effects of dopamine agonists on young Parkinson’s patients. Brain, 132, 2385–2395.PubMedCentralCrossRefPubMed

Burns, G. L., Keortge, S., Formea, G., & Sternberger, L. (1996). Revision of the Padua Inventory of obsessive–compulsive disorder symptoms: Distinctions between worry, obsessions, and compulsions. Behaviour Research and Therapy, 34, 163–173.CrossRefPubMed

Ceravolo, R., Frosini, D., Rossi, C., & Bonucell, U. (2010). Impulse control disorders in Parkinson’s disease: Definition, epidemiology, risk factors, neurobiology and management. Parkinsonism and Related Disorders, 155, 111–115.

Christenson, G., Faber, J., de Zwann, M., Raymond, N., Specker, S., Ekern, M., et al. (1994). Compulsive buying: Descriptive characteristics and psychiatric comorbidity. Journal of Clinical Psychiatry, 55(1), 5–11.PubMed

Crockford, D., Quickfall, J., Currie, S., Furtado, S., Suchowersky, O., & el-Guebaly, N. (2008). Prevalence of problem and pathological gambling in Parkinson’s disease. Journal of Gambling Studies, 24(4), 411–422.CrossRefPubMed

Cyders, M. A., & Smith, G. T. (2007). Mood-based rash action and its components: Positive and negative urgency. Personality and Individual Differences, 43, 839–850.CrossRef

Djamshidian, A., Cardosos, F., Grosset, D., Bowden-Jones, H., & Lees, A. (2011). Pathological gambling in Parkinson’s Disease: A review of the Literature. Movement Disorders, 26(11), 1976–1984.CrossRefPubMed

Dodd, M., Klos, K., Bower, J., Geda, Y., Joesps, K., & Ahlskog, E. (2005). Pathological gambling caused by drugs used to treat Parkinson’s disease. Archives of Neurology, 62, 1–5.CrossRef

Drapier, D., Drapier, S., Sauleau, P., Derkinderen, P., Damier, P., Allain, H., et al. (2006). Pathological gambling secondary to dopaminergic therapy in Parkinson’s. Psychiatry Research, 44(2–3), 241–244.CrossRef

Driver-Dunckley, E., Samanta, J., & Stacy, M. (2003). Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology, 61, 422–423.CrossRefPubMed

Eisen, S. (1996). Behavior and Symptom Identification Scale (BASIS-32). In L. Sederer & B. Dickey (Eds.), Outcomes assessment in clinical practice (pp. 65–69). Baltimore: Williams and Wilkins.

Evans, A., Lawrence, A., Potts, J., Appel, S., & Lees, A. (2005). Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson’s disease. Neurology, 65, 1570–1574.CrossRefPubMed

Evans, A., Strafella, A., Weintraub, D., & Stacy, M. (2009). Impulsive and compulsive behaviors in Parkinson’s disease. Movement Disorders, 24(11), 1561–1570.CrossRefPubMed

Ferris, J., & Wynne, H. (2001). The Canadian Problem Gambling Index: Final report. Ottawa: Canadian Centre on Substance Abuse.

Folstein, M., Folstein, S., & McHugh, P. (1975). Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.CrossRefPubMed

Fung, V., Hely, M., De Moore, G., & Morris, J. (2001). Drugs for Parkinson’s disease. Australian Prescriber, 24(4), 92–95.

Grosset, K., Macphee, G., Pal, G., Stewart, D., Watt, A., & Grosset, D. (2006). Problematic gambling on dopamine agonists: Not such a rarity. Movement Disorder, 21, 2206–2208.CrossRef

Gschwandtner, U., Aston, J., Renaud, S., & Fuhr, P. (2001). Pathological gambling in patients with Parkinson’s disease. Clinical Neuropharmacology, 24, 170–172.CrossRefPubMed

Hermann, C. (1996). International experiences with the Hospital Anxiety and Depression Scale: A review of validation data and clinical results. Journal of Psychosomatic Research, 42, 17–41.CrossRef

Hoehn, M., & Yahr, M. (1967). Parkinsonism: Onset, progression and mortality. Neurology, 17(5), 427–442.CrossRefPubMed

Jankovic, J. (2008). Parkinson’s disease: Clinical features and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 79, 368–376.CrossRefPubMed

Komadina, N., Terpening, Z., Huang, Y., Halliday, G., Naismith, S., & Lewis, S. (2011). Utility and limitations of Addenbrooke’s Cognitive Examination Revised for Detecting Mild Cognitive Impairment in Parkinson’s Disease. Dementia and Geriatric Cognitive Disorders, 31, 349–357.CrossRefPubMed

Lauterbach, E. (2004). The Neuropsychiatric of Parkinson’s disease and related disorders. Psychiatric Clinics of North America, 27, 805–824.CrossRef

Lemke, M., Fuchs, G., Gemende, I., Herting, B., Oehlwein, C., Reichmann, H., et al. (2004). Depression and Parkinson’s disease. Journal of Neurology, 251(l6), 24–27.

Lesieur, H. R., & Blume, S. B. (1987). The South Oaks Gambling Screen (SOGS): A new instrument for the identification of pathological gamblers. American Journal of Psychiatry, 144(9), 1184–1188.CrossRefPubMed

Lu, C., Bharmal, A., & Suchowersky, O. (2006). Gambling and Parkinson’s disease. Archives of Neurology, 63(2), 298.CrossRefPubMed

Lynam, D., Smith, G., Whiteside, S. P., & Cyders, M. (2006). The UPPS-P: Assessing five personality pathways to impulsive behavior. Technical report, Purdue University, West Lafayette.

Mamikonyan, E., Siderowf, A., Duda, J., Potenza, M., Horn, S., & Stern, M. (2008). Long-term follow-up of impulse control disorders in Parkinson’s disease. Movement Disorders, 23(1), 75–80.PubMedCentralCrossRefPubMed

Mioshi, E., Dawson, K., Mitchell, J., Arnold, R., & Hodges, J. (2006). The Addenbrooke’s Cognitive Examination Revised (ACE-R): A brief cognitive test battery for dementia screening. International Journal of Geriatric Psychiatry, 21(11), 1078–1085.CrossRefPubMed

Nower, L., & Blaszczynski, A. (2008). Characteristics of problem gamblers 56 years of age or older: A statewide study of casino self-excluders. Psychology and Aging, 23(3), 577–584.CrossRefPubMed

Pandya, M., Kubu, C., & Giroux, M. (2008). Parkinson disease: Not just a movement disorder. Cleveland Journal of Medicine, 75(12), 856–864.CrossRef

Petry, N. (2005). Pathological gambling: Etiology, comorbidity, and treatment. Washington, DC: American Psychological Association.CrossRef

Petry, N., Stinson, F., & Grant, B. (2005). Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: Results from the national epidemiologic survey on alcohol and related conditions. The Journal of Clinical Psychiatry, 66, 564–574.CrossRefPubMed

Potenza, M., & Hollander, E. (2002). Pathological gambling and impulse control disorders. In D. Charney, K. L. Davis, J. T. Coyle, & C. Nemeroff (Eds.), Neuropsychopharmacology: The 5th generation of progress. Baltimore, MD: Lippincott Williams and Wilkins.

Raylu, N., & Oei, T. (2002). Pathological gambling: A comprehensive review. Clinical Psychology Review, 22, 1009–1061.CrossRefPubMed

Rodriguez-Blazquez, C., Frades-Payo, B., Forjaz, M., Peddo-Cuesta, J., & Martinez-Martin, P. (2009). Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson’s disease. Movement Disorders, 24(4), 519–525.CrossRefPubMed

Sanavio, E. (1988). Obsessions and compulsions: The Padua Inventory. Behaviour Research and Therapy, 26(2), 169–177.CrossRefPubMed

Savard, J., Laberge, B., Gauthier, J., Ivers, H., & Bergeron, M. (1998). Evaluating anxiety and depression in HIV-infected patients. Journal of Personality Assessment, 71(3), 349–367.CrossRefPubMed

Sharpe, L., & Tarrier, N. (1993). Towards a cognitive-behavioural theory of problem gambling. British Journal of Psychiatry, 162, 407–412.CrossRefPubMed

Singh, A., Kandamala, G., Dewey, R., & O’Suilleabhain, P. (2007). Risk factors for pathological gambling and other compulsion among Parkinson’s disease patients taking dopamine agonists. Journal of Clinical Neuroscience, 14, 1178–1181.CrossRefPubMed

Smith, G., Annus, A., & Zapolski, T. (2007). Theory and test validation: A practical example. In M. Lange (Ed.), Leading-edge psychological tests and testing (pp. 51–70). New York: Nova Science.

Steele, Z., & Blaszczynski, A. (1998). Impulsivity, personality disorders and pathological gambling severity. Addiction, 93, 895–905.CrossRef

Stinchfield, R., & Winters, K. (1996). Effectiveness of six state-supported compulsive gambling treatment programs in Minnesota. Minnesota: Department of Human Services.

Sunderwirth, S., & Milkman, H. (1991). Behavioral and neurochemical commonalities in addiction. Contemporary Family Therapy, 13(5), 421–433.CrossRef

Voon, V., & Fox, S. (2007). Medication-related impulse control and repetitive behaviours in Parkinson’s disease. Neurological Review, 64(8), 1089–1096.

Voon, V., Hassan, K., de Zurowski, M., Souza, M., Thomsen, T., Fox, S., et al. (2006a). Prevalence of repetitive and reward-seeking behaviors in Parkinson’s disease. Neurology, 67(7), 1254–1257.CrossRefPubMed

Voon, V., Hassan, K., Zurowski, M., Duff-Canning, S., de Souza, M., & Fox, S. (2006b). Prospective prevalence of pathologic gambling and medication association with Parkinson’s disease. Neurology, 66, 1750–1752.CrossRefPubMed

Voon, V., Pessiglione, M., Brezing, C., Gallea, C., Fernandez, H., Dolan, R., et al. (2011). Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron, 65(1), 135–142.CrossRef

Voon, V., Thomsen, T., Miyasaki, J., de Souza, M., Sharfo, A., Fox, S., et al. (2007). Factors associated with dopaminergic drug-related pathological gambling in Parkinson’s disease. Archives of Neurology, 6, 21–216.

Weinstock, J., Whelan, J., & Meyers, A. (2004). Behavioral assessment of gambling: An application of the timeline followback method. Psychological Assessment, 16, 72–80.CrossRefPubMed

Weintraub, D., Koester, J., Potenza, M., Siderwof, A., Stacy, M., Voon, V., et al. (2010). Impulse control disorders in Parkinson’s disease. Archives of Neurology, 67(5), 589–595.CrossRefPubMed

Weintraub, D., Siderowf, A., Potenza, M., Goevas, J., Morales, K., Duda, J., et al. (2006). Association of dopamine agonist use with impulse control disorders in Parkinson’s disease. Archives of Neurology, 63, 969–973.PubMedCentralCrossRefPubMed

Weintraub, D., Stewart, S., Shea, J., Lyons, K., Pahwa, R., Driver-Dunckley, E., et al. (2009). Validation of the questionnaire for impulsive–compulsive behaviors in Parkinson’s Disease (QUIP). Movement Disorders, 24, 1461–1467.PubMedCentralCrossRefPubMed

Whiteside, S., & Lynam, D. (2001). The Five Factor Model and impulsivity: Using a structural model of personality to understand impulsivity. Personality and Individual Differences, 30, 669–689.CrossRef

Zigmund, A., & Snaith, R. (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatry Scandinavia, 67, 361–370.CrossRef

Titel: Dopaminergic Medication in Parkinson’s Disease and Problem Gambling
verfasst von: Jacqueline Olley
Alex Blaszczynski
Simon Lewis
Publikationsdatum: 01.09.2015
Verlag: Springer US
Erschienen in: Journal of Gambling Studies / Ausgabe 3/2015
Elektronische ISSN: 1573-3602
DOI: https://doi.org/10.1007/s10899-014-9503-0

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Reliability and Validity of Three Instruments (DSM-IV, CPGI, and PPGM) in the Assessment of Problem Gambling in South Korea

Validation of the Gambling Motives Questionnaire in Emerging Adults

Demographic Risk Factors and Gambling Preference May Not Explain the High Prevalence of Gambling Problems Among the Population with Migration Background: Results from a German Nationwide Survey

Emotional and Social Factors influence Poker Decision Making Accuracy

Congruence Couple Therapy for Pathological Gambling: A Pilot Randomized Controlled Trial

Smoking and Gambling Disorder: Does Tobacco Use Influence Treatment Outcome?

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein